CN117752667A - Traditional Chinese medicine composition, preparation method and application thereof - Google Patents
Traditional Chinese medicine composition, preparation method and application thereof Download PDFInfo
- Publication number
- CN117752667A CN117752667A CN202311803810.6A CN202311803810A CN117752667A CN 117752667 A CN117752667 A CN 117752667A CN 202311803810 A CN202311803810 A CN 202311803810A CN 117752667 A CN117752667 A CN 117752667A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- forsythoside
- chinese medicine
- parts
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- JMBINOWGIHWPJI-UNSOMVRXSA-N [(2r,3r,4r,5r,6r)-2-[[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@](O)(CO)CO2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O JMBINOWGIHWPJI-UNSOMVRXSA-N 0.000 claims abstract description 53
- 241000546273 Lindera <angiosperm> Species 0.000 claims abstract description 29
- JMBINOWGIHWPJI-UHFFFAOYSA-N pedicularoside A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)C(COC2C(C(O)(CO)CO2)O)OC(OCCC=2C=C(O)C(O)=CC=2)C1O JMBINOWGIHWPJI-UHFFFAOYSA-N 0.000 claims abstract description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 25
- -1 ether lactone Chemical class 0.000 claims abstract description 25
- 150000002338 glycosides Chemical class 0.000 claims abstract description 15
- 241000123346 Chrysosporium Species 0.000 claims abstract description 14
- 229930182470 glycoside Natural products 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229950004403 polifeprosan Drugs 0.000 claims abstract description 5
- 239000002671 adjuvant Substances 0.000 claims abstract description 3
- 239000012467 final product Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000002884 effect on inflammation Effects 0.000 abstract description 3
- 239000013641 positive control Substances 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- QIMGUQIHCNDUKU-UHFFFAOYSA-N 2-[[6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OCCC=2C=C(O)C(O)=CC=2)O1 QIMGUQIHCNDUKU-UHFFFAOYSA-N 0.000 description 1
- 241001438943 Callicarpa kwangtungensis Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229930190674 chrysosplenoside Natural products 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930189432 forsythoside Natural products 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 18 to 22 parts of forsythoside B, 18 to 22 parts of chrysosporium glycoside and 8 to 12 parts of lindera root ether lactone. The preparation method comprises the following steps: mixing forsythoside B, polifeprosan and lindera root ether lactone, and adding pharmaceutically acceptable adjuvants to obtain the final product. The traditional Chinese medicine composition is prepared from forsythoside B, chrysosporium glycoside and lindera root ether lactone by scientific compatibility, and proved by experiments, the traditional Chinese medicine composition is prepared from the forsythoside B, the chrysosporium glycoside and the lindera root ether lactone by scientific compatibility: when forsythoside B, chrysosporidine and lindera root ether lactone are combined, the inhibition effect on inflammation is equivalent to that of aspirin (positive control) and is obviously better than that of anti-inflammatory effect of each medicament used independently.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof.
Background
At present, antibiotics (such as amoxicillin, azithromycin and the like) are commonly adopted for treating the inflammation at home and abroad, the side effect is large, the drug resistance is easy to appear when the medicine is repeatedly used for many times, the important organs such as the liver, the kidney and the like are greatly influenced, and certain injuries can be caused to the crossed nerves and the blood system of people when the antibiotics are frequently taken.
Therefore, research on the treatment of various inflammations using natural active substances with little toxic and side effects is getting more and more attention. Based on the above, the technical scheme of the invention is also provided.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a traditional Chinese medicine composition, which comprises the following raw materials: forsythoside B, chrysosporin and lindera root ether lactone.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 18 to 22 parts of forsythoside B, 18 to 22 parts of chrysosporium glycoside and 8 to 12 parts of lindera root ether lactone.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20 parts of forsythoside B, 20 parts of chrysosporium glycoside and 10 parts of lindera root ether lactone.
Based on the same technical conception, a still another scheme of the invention is to provide a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
mixing forsythoside B, polifeprosan and lindera root ether lactone, and adding pharmaceutically acceptable adjuvants to obtain the final product.
Preferably, the traditional Chinese medicine composition is an oral preparation.
Preferably, the oral preparation is a tablet, capsule, granule, pill, controlled release preparation or sustained release preparation.
Based on the same technical conception, another scheme of the invention is to provide an application of the traditional Chinese medicine composition in preparing anti-inflammatory medicines.
The beneficial effects of the invention are as follows:
the traditional Chinese medicine composition is prepared from forsythoside B, chrysosporium glycoside and lindera root ether lactone by scientific compatibility, and proved by experiments, the traditional Chinese medicine composition is prepared from the forsythoside B, the chrysosporium glycoside and the lindera root ether lactone by scientific compatibility: when forsythoside B, chrysosporidine and lindera root ether lactone are combined, the inhibition effect on inflammation is equivalent to that of aspirin (positive control) and is obviously better than that of anti-inflammatory effect of each medicament used independently.
The preparation method of the traditional Chinese medicine composition provided by the invention has the advantages that the process is simple, convenient and easy to control, and the large-scale production is facilitated.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, based on the examples herein, which are within the scope of the invention as defined by the claims, will be within the scope of the invention as defined by the claims.
Example 1
The embodiment provides a preparation method of a traditional Chinese medicine composition, which comprises the following steps:
(I) The preparation method of forsythoside B and chrysosporidine comprises the following steps:
taking dry stem, branch and leaf coarse powder of Callicarpa kwangtungensis, soaking with water, reflux-extracting with 8-12 times of solvent for 2-4 times, each time for 1-3 hours, filtering, mixing filtrates, concentrating to relative density of 1.10-1.25, sequentially extracting with equal volume of ethyl acetate and water saturated n-butanol respectively for three times, collecting n-butanol extract, and concentrating under reduced pressure to dry. Dissolving n-butanol extract in water, loading on D101 macroporous resin column, eluting with water, 30% ethanol, 50% ethanol and 95% ethanol, collecting 30% ethanol fraction, concentrating under reduced pressure to dry, adding equal amount of reverse phase silica gel, stirring, preparing liquid chromatographic column under medium pressure, eluting with acetonitrile-water (85:15) at equal degree, collecting corresponding fractions every 500mL, mixing, concentrating under reduced pressure, and obtaining forsythoside B from fractions 13-22, wherein the yields of the fractions 36-45 are 1% -2% and 0.5% -1%, respectively, and the purities are 92% -95%.
The preparation method of the lindera root ether lactone (II) comprises the following steps:
slicing radix Linderae, decocting in water for 2 times each for 2 hr, filtering, mixing filtrates, concentrating to soft extract, drying under reduced pressure, and mixing with diatomite; filling 3-6 pieces of filter paper at the bottom of the extraction tank, and adding diatomite as a bottom layer; adding the mixture of the lindera root extract and the diatomite into an extraction tank; adding a proper amount of diatomite into the extraction tank to serve as a surface layer substance; extracting by adopting a mixed solution of acetonitrile and normal hexane, wherein the temperature is 80 ℃; pouring the extract into an evaporating dish, rinsing the receiving bottle with a small amount of acetonitrile and n-hexane mixed solution with the volume ratio of 1:2, merging the extract, and evaporating to dryness to obtain the lindera root ethereal lactone.
Preparation of the traditional Chinese medicine composition:
mixing forsythoside B22 g, poliomyelitis glucoside 22g and lindera root ether lactone 12g, adding pharmaceutically acceptable auxiliary materials, granulating, drying, mixing, and tabletting to obtain Chinese medicinal composition tablet.
Example 2
The present embodiment provides a method for preparing a traditional Chinese medicine composition, which is different from embodiment 1 only in step (III), where step (III) of the present embodiment is:
adding pharmaceutically acceptable auxiliary materials into 18g of forsythoside B, 18g of polifeprosan and 8g of lindera root ether lactone, granulating, drying and mixing to obtain the traditional Chinese medicine composition capsule.
The rest of the procedure is the same as in example 1.
Example 3
The present embodiment provides a method for preparing a traditional Chinese medicine composition, which is different from embodiment 1 only in step (III), where step (III) of the present embodiment is:
adding pharmaceutically acceptable auxiliary materials into 20g of forsythoside B, 20g of polifeprosan and 10g of lindera root ether lactone, granulating, drying and mixing to obtain the traditional Chinese medicine composition granules.
The rest of the procedure is the same as in example 1.
Example 4
The present embodiment provides a method for preparing a Chinese medicinal composition, which is different from embodiment 1 only in the dosage form of the final Chinese medicinal composition, and the final Chinese medicinal composition pill is obtained in this embodiment.
The rest of the procedure is the same as in example 1.
Example 5
The present embodiment provides a method for preparing a traditional Chinese medicine composition, which is different from embodiment 1 only in the dosage form of the final traditional Chinese medicine composition, and the controlled release preparation of the traditional Chinese medicine composition is finally obtained in this embodiment.
The rest of the procedure is the same as in example 1.
Example 6
The present embodiment provides a method for preparing a traditional Chinese medicine composition, which is different from embodiment 1 only in the dosage form of the final traditional Chinese medicine composition, and the embodiment finally obtains a slow-release preparation of the traditional Chinese medicine composition.
The rest of the procedure is the same as in example 1.
Comparative example
The invention adopts a mouse foot swelling method to evaluate the inhibition effect of different drugs on inflammatory reaction.
The test animals were: healthy male mice, weighing 20 g+ -2 g;
the test drugs are: aspirin, forsythoside B, chrysosporidine, lindera root ether lactone;
the test instrument is as follows: mouse foot swelling meter.
Mice were randomly divided into 9 groups of 6 mice each:
(1) Forsythoside B group; (2) a group of chrysosporium glycosides; (3) lindera root etherlactone group; (4) forsythoside B and a group of chrysosplenoside; (5) forsythoside B and lindera root ether lactone group; (6) a group of chrysosporium glycosides and lindera root etherlactones; (7) Forsythoside B, a combination of chrysosporium glycoside and lindera root ether lactone; (8) a blank group; (9) Aspirin control group.
The experimental steps are as follows: after 30min, 0.1mol of 0.1% ovalbumin solution was injected into the left hind sole of each group of mice, and after 1-5 hours of injection, the swelling degree of the feet of the mice was measured and recorded, and the recording results are shown in table 1.
TABLE 1
As can be seen from the results in table 1, when forsythoside B, chrysosporium glycoside and lindera root ether lactone are used singly or in combination, the anti-inflammatory effect is not significantly different from that of the blank control group; when forsythoside B, chrysosporium glycoside and lindera root ether lactone are combined, the inhibition effect on inflammation is equivalent to that of aspirin (positive control) and is obviously better than that of anti-inflammatory effect of each medicament used independently.
The foregoing is merely illustrative of the present invention, and the present invention is not limited thereto, and any person skilled in the art will readily recognize that variations or substitutions are within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (7)
1. A Chinese medicinal composition is characterized by comprising the following raw materials: forsythoside B, chrysosporin and lindera root ether lactone.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 18 to 22 parts of forsythoside B, 18 to 22 parts of chrysosporium glycoside and 8 to 12 parts of lindera root ether lactone.
3. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 20 parts of forsythoside B, 20 parts of chrysosporium glycoside and 10 parts of lindera root ether lactone.
4. The method for preparing the traditional Chinese medicine composition according to any one of claims 1 to 3, which is characterized in that the method for preparing comprises the following steps:
mixing forsythoside B, polifeprosan and lindera root ether lactone, and adding pharmaceutically acceptable adjuvants to obtain the final product.
5. The method for preparing a Chinese medicinal composition according to claim 4, wherein the Chinese medicinal composition is an oral preparation.
6. The method of preparing a pharmaceutical composition according to claim 5, wherein the oral formulation is a tablet, capsule, granule, pill, controlled release formulation or sustained release formulation.
7. Use of a Chinese medicinal composition according to any one of claims 1 to 3 in the preparation of anti-inflammatory medicaments.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311803810.6A CN117752667A (en) | 2023-12-26 | 2023-12-26 | Traditional Chinese medicine composition, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311803810.6A CN117752667A (en) | 2023-12-26 | 2023-12-26 | Traditional Chinese medicine composition, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117752667A true CN117752667A (en) | 2024-03-26 |
Family
ID=90314024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311803810.6A Pending CN117752667A (en) | 2023-12-26 | 2023-12-26 | Traditional Chinese medicine composition, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117752667A (en) |
-
2023
- 2023-12-26 CN CN202311803810.6A patent/CN117752667A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105012455A (en) | Pain-easing hemostasis medicine and preparation method and application thereof | |
| CN101700289B (en) | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments | |
| CN1241574C (en) | Medicine for relieving spasm and pain and preparation process thereof | |
| CN1973853B (en) | Hemostatic and analgetic medicine composition and its preparation process | |
| CN117752667A (en) | Traditional Chinese medicine composition, preparation method and application thereof | |
| CN102302615A (en) | Effective site group of daphne giraldii nitsche leaf, preparation method, medicinal composition and application thereof | |
| CN101455778B (en) | Traditional Chinese medicine preparation capable of reducing fever and relieving sore-throat and preparation method thereof | |
| CN101147767B (en) | Preparation method of medicinal composition for treating acne | |
| CN1323682C (en) | Chinese medicine preparation of infectious external contraction high fever and production thereof | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN1321632C (en) | Compound saussurea involucrata capsule and its preparation process | |
| CN102755396A (en) | Preparation process and matrix for gel cream for treating coronary heart disease | |
| CN101904906B (en) | Rhizoma corydalis pain-relieving dripping pill preparation and preparation process thereof | |
| CN101496868A (en) | Medicament composition | |
| CN108864128A (en) | Four kinds of guassin industrial production process and its prepare drug, health food new application | |
| CN101693052A (en) | Violet light pellet and preparation method thereof | |
| CN1895407A (en) | Zhisou and phlegm-eliminating Chinese medicinal preparation and its making method | |
| CN101313972A (en) | Technique for preparing new preparation of six ingredients with rehmannia | |
| CN101147766A (en) | Medicinal composition for treating acne and preparation process thereof | |
| CN1362166A (en) | Nano four-drug medicine and its preparation | |
| CN104740234A (en) | Chinese medicinal composition and preparation method thereof | |
| CN103735591A (en) | Composition for treating digestive ulcer and applications thereof | |
| CN111939150A (en) | Application of loganin aglycone in preparation of medicine for preventing or treating liver injury or liver failure | |
| CN101890036B (en) | Application of astragaloside | |
| CN111870626A (en) | Pharmaceutical composition with blood fat reducing effect and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination |